Y2 Antagonist 36

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 527465

CAS#: 1185845-15-1

Description: Y2 Antagonist 36 is a novel non-peptidic highly potent, soluble and selective NPY Y2 antagonist.


Chemical Structure

img
Y2 Antagonist 36
CAS# 1185845-15-1

Theoretical Analysis

MedKoo Cat#: 527465
Name: Y2 Antagonist 36
CAS#: 1185845-15-1
Chemical Formula: C27H29ClN4O3
Exact Mass: 492.1928
Molecular Weight: 493.004
Elemental Analysis: C, 65.78; H, 5.93; Cl, 7.19; N, 11.36; O, 9.74

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Synonym: Y2 Antagonist 36

IUPAC/Chemical Name: N-[3-Chloro-4-[4-(3-methoxypyridine-2-carbonyl)piperazin-1-yl]phenyl]-2-methyl-2-phenylpropanamide

InChi Key: WIHRUDKZTYLJLT-UHFFFAOYSA-N

InChi Code: InChI=1S/C27H29ClN4O3/c1-27(2,19-8-5-4-6-9-19)26(34)30-20-11-12-22(21(28)18-20)31-14-16-32(17-15-31)25(33)24-23(35-3)10-7-13-29-24/h4-13,18H,14-17H2,1-3H3,(H,30,34)

SMILES Code: CC(C1=CC=CC=C1)(C)C(NC2=CC=C(N3CCN(C(C4=NC=CC=C4OC)=O)CC3)C(Cl)=C2)=O

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

Preparing Stock Solutions

The following data is based on the product molecular weight 493.004 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Domingues MF, de Assis DR, Piovesan AR, Belo CAD, da Costa JC. Peptide YY (3-36) modulates intracellular calcium through activation of the phosphatidylinositol pathway in hippocampal neurons. Neuropeptides. 2017 Nov 7. pii: S0143-4179(16)30200-1. doi: 10.1016/j.npep.2017.11.003. [Epub ahead of print] PubMed PMID: 29157865.

2: Kojima SI, Kojima K, Fujita T. Investigation of 5-HT(3) receptor-triggered serotonin release from guinea-pig isolated colonic mucosa: a role of PYY-containing endocrine cell. Eur J Pharmacol. 2017 Mar 15;799:196-200. doi: 10.1016/j.ejphar.2017.02.011. Epub 2017 Feb 9. PubMed PMID: 28189582.

3: Hassan AM, Jain P, Mayerhofer R, Fröhlich EE, Farzi A, Reichmann F, Herzog H, Holzer P. Visceral hyperalgesia caused by peptide YY deletion and Y2 receptor antagonism. Sci Rep. 2017 Jan 20;7:40968. doi: 10.1038/srep40968. PubMed PMID: 28106168; PubMed Central PMCID: PMC5247702.

4: Alhadeff AL, Golub D, Hayes MR, Grill HJ. Peptide YY signaling in the lateral parabrachial nucleus increases food intake through the Y1 receptor. Am J Physiol Endocrinol Metab. 2015 Oct 15;309(8):E759-66. doi: 10.1152/ajpendo.00346.2015. Epub 2015 Sep 1. PubMed PMID: 26330345; PubMed Central PMCID: PMC4609877.

5: Verma D, Wood J, Lach G, Mietzsch M, Weger S, Heilbronn R, Herzog H, Bonaventure P, Sperk G, Tasan RO. NPY Y2 receptors in the central amygdala reduce cued but not contextual fear. Neuropharmacology. 2015 Dec;99:665-74. doi: 10.1016/j.neuropharm.2015.08.038. Epub 2015 Aug 24. PubMed PMID: 26314208.

6: Xu B, Fällmar H, Boukharta L, Pruner J, Lundell I, Mohell N, Gutiérrez-de-Terán H, Aqvist J, Larhammar D. Mutagenesis and computational modeling of human G-protein-coupled receptor Y2 for neuropeptide Y and peptide YY. Biochemistry. 2013 Nov 12;52(45):7987-98. doi: 10.1021/bi400830c. Epub 2013 Oct 31. PubMed PMID: 24111902.

7: Chandarana K, Gelegen C, Irvine EE, Choudhury AI, Amouyal C, Andreelli F, Withers DJ, Batterham RL. Peripheral activation of the Y2-receptor promotes secretion of GLP-1 and improves glucose tolerance. Mol Metab. 2013 Mar 14;2(3):142-52. doi: 10.1016/j.molmet.2013.03.001. eCollection 2013. PubMed PMID: 24049729; PubMed Central PMCID: PMC3773824.

8: Teubner BJ, Bartness TJ. PYY(3-36) into the arcuate nucleus inhibits food deprivation-induced increases in food hoarding and intake. Peptides. 2013 Sep;47:20-8. doi: 10.1016/j.peptides.2013.05.005. Epub 2013 Jun 29. PubMed PMID: 23816798; PubMed Central PMCID: PMC3759582.

9: Stadlbauer U, Langhans W, Meyer U. Administration of the Y2 receptor agonist PYY3-36 in mice induces multiple behavioral changes relevant to schizophrenia. Neuropsychopharmacology. 2013 Nov;38(12):2446-55. doi: 10.1038/npp.2013.146. Epub 2013 Jun 10. PubMed PMID: 23748226; PubMed Central PMCID: PMC3799064.

10: Reidelberger R, Haver A, Chelikani PK. Role of peptide YY(3-36) in the satiety produced by gastric delivery of macronutrients in rats. Am J Physiol Endocrinol Metab. 2013 May 1;304(9):E944-50. doi: 10.1152/ajpendo.00075.2013. Epub 2013 Mar 12. PubMed PMID: 23482449; PubMed Central PMCID: PMC3651646.

11: Wu W, Bates MA, Bursian SJ, Flannery B, Zhou HR, Link JE, Zhang H, Pestka JJ. Peptide YY3-36 and 5-hydroxytryptamine mediate emesis induction by trichothecene deoxynivalenol (vomitoxin). Toxicol Sci. 2013 May;133(1):186-95. doi: 10.1093/toxsci/kft033. Epub 2013 Mar 1. PubMed PMID: 23457120; PubMed Central PMCID: PMC3627556.

12: Veyrat-Durebex C, Quirion R, Ferland G, Dumont Y, Gaudreau P. Aging and long-term caloric restriction regulate neuropeptide Y receptor subtype densities in the rat brain. Neuropeptides. 2013 Jun;47(3):163-9. doi: 10.1016/j.npep.2013.01.001. Epub 2013 Feb 12. PubMed PMID: 23410741.

13: dos Santos VV, Santos DB, Lach G, Rodrigues AL, Farina M, De Lima TC, Prediger RD. Neuropeptide Y (NPY) prevents depressive-like behavior, spatial memory deficits and oxidative stress following amyloid-β (Aβ(1-40)) administration in mice. Behav Brain Res. 2013 May 1;244:107-15. doi: 10.1016/j.bbr.2013.01.039. Epub 2013 Feb 5. PubMed PMID: 23396168.

14: Trent NL, Menard JL. Lateral septal infusions of the neuropeptide Y Y2 receptor agonist, NPY(13-36) differentially affect different defensive behaviors in male, Long Evans rats. Physiol Behav. 2013 Feb 17;110-111:20-9. doi: 10.1016/j.physbeh.2012.12.011. Epub 2012 Dec 28. PubMed PMID: 23274501.

15: Rosmaninho-Salgado J, Cortez V, Estrada M, Santana MM, Gonçalves A, Marques AP, Cavadas C. Intracellular mechanisms coupled to NPY Y2 and Y5 receptor activation and lipid accumulation in murine adipocytes. Neuropeptides. 2012 Dec;46(6):359-66. doi: 10.1016/j.npep.2012.08.006. Epub 2012 Sep 13. PubMed PMID: 22981159.

16: Sparrow AM, Lowery-Gionta EG, Pleil KE, Li C, Sprow GM, Cox BR, Rinker JA, Jijon AM, Peňa J, Navarro M, Kash TL, Thiele TE. Central neuropeptide Y modulates binge-like ethanol drinking in C57BL/6J mice via Y1 and Y2 receptors. Neuropsychopharmacology. 2012 May;37(6):1409-21. doi: 10.1038/npp.2011.327. Epub 2012 Jan 4. PubMed PMID: 22218088; PubMed Central PMCID: PMC3327846.

17: Stadler J, Le TP, Haas P, Nave H. Distinct effects of NPY13-36, a specific NPY Y2 agonist, in a model of rodent endotoxemia on leukocyte subsets and cytokine levels. Ann Anat. 2011 Dec 20;193(6):486-93. doi: 10.1016/j.aanat.2011.10.009. Epub 2011 Oct 21. PubMed PMID: 22074679.

18: Morales-Medina JC, Dumont Y, Benoit CE, Bastianetto S, Flores G, Fournier A, Quirion R. Role of neuropeptide Y Y₁ and Y₂ receptors on behavioral despair in a rat model of depression with co-morbid anxiety. Neuropharmacology. 2012 Jan;62(1):200-8. doi: 10.1016/j.neuropharm.2011.06.030. Epub 2011 Jul 23. PubMed PMID: 21803058.

19: Pop N, Igel P, Brennauer A, Cabrele C, Bernhardt GN, Seifert R, Buschauer A. Functional reconstitution of human neuropeptide Y (NPY) Y(2) and Y(4) receptors in Sf9 insect cells. J Recept Signal Transduct Res. 2011 Aug;31(4):271-85. doi: 10.3109/10799893.2011.583253. PubMed PMID: 21745157.

20: Fällmar H, Åkerberg H, Gutiérrez-de-Terán H, Lundell I, Mohell N, Larhammar D. Identification of positions in the human neuropeptide Y/peptide YY receptor Y2 that contribute to pharmacological differences between receptor subtypes. Neuropeptides. 2011 Aug;45(4):293-300. doi: 10.1016/j.npep.2011.05.006. Epub 2011 Jun 22. PubMed PMID: 21696823.